GSK

GlaxoSmithKline

NYSE

Add Alert

GSK

GlaxoSmithKline

NYSE

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Monksdream PremiumMember

02/16/24 2:15 PM

Post #184

GSK new 52 week high

Monksdream PremiumMember

01/15/24 2:54 PM

Post #183

GSK new 52 week high

Monksdream PremiumMember

01/09/24 2:11 PM

Post #182

GSK new 52 week high

1jas

08/25/23 8:48 PM

Post #180

has anybody here seen that enzolytics pharm announced that they have a cure for hiv/aids yesterday.

MrHankey

07/18/23 12:16 AM

Post #179

Does the name Christian Lamarco (www.culperresearch.com) mean anything to you?
If not, you should know that this "activist investor" (aka "short") has requested through FOIA from the FDA for the below information. Prepare for a hit piece and a stock drop.

"Requesting copies of the letter and/or all communications from the FDA to GSK requesting the withdrawal of GSK's Blenrep from the market in the US, as widely reported in November 2022."

https://www.fda.gov/media/170006/download

Magnum7419 Free

06/12/23 9:08 AM

Post #178

i am in 100@ 34.56 :)

Magnum7419 Free

06/11/23 10:05 PM

Post #177

Re: #175: @BottomBounce - $GSK Total Debt is $22.11 Billion // $8.00

GSK #1 pick!!

Bullish

jondoeuk

09/13/22 12:41 PM

Post #176

Post hoc analysis shows that biomarker correlates with response to NY-ESO-1 TCR-T cells in patients with synovial sarcoma https://www.nature.com/articles/s41467-022-32491-x

BottomBounce Free

08/11/22 9:02 AM

Post #175

Re: #174: @rosemountbomber - Anyone know how we will calculate our cost

$GSK Total Debt is $22.11 Billion // $8.00 should be trading

rosemountbomber Free

07/22/22 5:19 AM

Post #174

Anyone know how we will calculate our cost basis in Haleon?

ruke

06/08/22 4:58 AM

Post #173

Re: #172: @jondoeuk - Complete Responses in 100% of dMMR Rectal Cancer

So, why shares aren't realy mooning in pre-market? Isn't that strange?

jondoeuk

06/06/22 1:02 PM

Post #172

Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition https://www.medpagetoday.com/meetingcoverage/asco/99071

jondoeuk

06/05/22 5:08 PM

Post #171

Lete-Cel ASCO data https://www.cgtlive.com/view/lete-cel-exhibits-anti-tumor-activity-long-median-pfs-patients-myxoid-round-cell-liposarcoma

jondoeuk

04/23/22 4:20 PM

Post #170

The company has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses LYEL's Epi-R https://lyell.com/our-platforms

4MVault

12/05/21 10:47 AM

Post #168

GSK Should buy ATOS

jondoeuk

06/05/21 12:24 PM

Post #167

New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

From it: ''These data provide an initial rationale as to how tumors with histologies resistant to checkpoint blockade can be successfully targeted with adoptive T-cell therapy. Furthermore, these data are the first to demonstrate successful infiltration of solid tumors by SPEAR T cells, which are able to kill tumor cells. Our data also suggest that antigen loss or alterations in the expression of antigen processing proteins are not primary mechanisms of resistance. Moreover, the therapeutic efficacy may be enhanced through use of a high dose fludarabine-containing preparative lymphodepletion regimen, by promoting greater engraftment at the tumor site, and through modulation of TAM.''

jondoeuk

05/26/21 8:48 PM

Post #166

Re: #164: @jondoeuk - Some more info https://lyell.com/our-platforms

They have shared some preclinical data https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165ds1.htm

jondoeuk

05/25/21 8:04 PM

Post #165

Re: #164: @jondoeuk - Some more info https://lyell.com/our-platforms

Preclinical data from another group: ''Hepatocellular carcinoma (HCC) is responsible for most of primary liver cancer cases and is the sixth most common cancer in the world with a general 5 year survival rate of 18% due to lack of effective therapy. Adoptive T-cell therapy (ACT) with T-cell receptor–engineered T-cell (TCR-T) against HCC-associated antigen a-fetoprotein (AFP), can redirect human T cells to recognize and kill HCC tumor cells.

However, the clinical efficacy of TCR-T therapy is dependent on the proper expansion, in vivo persistence of T cells that is markedly reduced due to exhaustion-associated dysfunction, and activation induced cell death. To improve persistence of TCR-T cells without modifying TCR affinity, we engineered TCR-T cells to overexpress c-Jun, an AP-1 transcription factor associated with T cell development and activation. In this study, we showed that TCR-T cells overexpressing c-Jun have enhanced expansion capacity in culture, improved cytokine production against HepG2 tumor cells without altering their cytotoxic potential.

Interestingly TCR-T cells overexpressing c-Jun showed resistance to activation induced cell death with decreased expression of inhibitory receptors after stimulation with HepG2 tumor cells. Thus, c-Jun overexpression could be a potential therapeutic agent to enhance the anti-tumor efficacy of TCR-T cells against HCC.''

https://virtual.aai.org/aai/2021/virtual-immunology-2021/317351/mohamed.hussein.the.role.of.c-jun.in.enhancing.tcr-t.function.in.treatment.of.html

jondoeuk

05/19/21 9:55 PM

Post #164

Re: #157: @jondoeuk - Lyell plan to use defined cell populations [1],

Some more info https://lyell.com/our-platforms

stillness0007 Free

05/01/21 9:52 AM

Post #163

GSK V TEVA question. The panel of judges heard the case on Feb 23rd. Am I right to understand, usually a decision is made 3-4 months after that? Cause some are saying by end of 2022, which makes no sense to me.

testing4covid Terminated

12/15/20 11:15 AM

Post #162

Achiko AG: The One Ecosystem that Takes a ‘Swiss Cheese’ Approach to COVID-19

Great article on an upcoming testing technology:

https://sponsored.bloomberg.com/news/sponsors/features/next-tech-stock/the-next-big-thing-in-health-tech/?adv=33197&prx_t=wmcGAAAAAAUk0NA&prx_ro=s&sref=GS2dzBte

whytestocks Free

11/15/20 2:15 PM

Post #161

Breaking News: $GSK Investors Wish They Could Vote These 2 Healthcare CEOs Out

One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management. But some investors might ...

Read the whole news GSK - Investors Wish They Could Vote These 2 Healthcare CEOs Out

jondoeuk

10/15/20 2:09 PM

Post #160

Re: #159: @jondoeuk - SITC Decitabine gene modulation sensitizes human non–small cell lung

Decitabine has been shown to induce cancer-testis antigen expression https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139221

jondoeuk

10/14/20 7:18 PM

Post #159

SITC

Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo

Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)

jondoeuk

09/12/20 1:12 PM

Post #158

Re: #155: @jondoeuk - A new trial testing the NY-ESO-1 TCR-T cell

Going forward, I would like them to transduce half of the CD4+ T-cells with an NY-ESO-1 specific MHC II restricted TCR [1], and the other half to co-express a CD8a. Combining both CD4+ and CD8+ can induce bystander killing of antigen-negative cancer cells [2,3]. Also, some of the CD4+ can show tumoricidal activity by their own means irrespective of MHC II expression [4-7].

Refs:
1 https://www.nejm.org/doi/full/10.1056/nejmoa0800251
2 https://rupress.org/jem/article/207/11/2469/40645/Bystander-killing-of-cancer-requires-the
3 https://www.nature.com/articles/srep14896
4 https://cancerres.aacrjournals.org/content/70/21/8368.long
5 https://rupress.org/jem/article/154/3/952/49262/Eradication-of-disseminated-murine-leukemia-by
6 https://rupress.org/jem/article/207/3/637/40473/Tumor-reactive-CD4-T-cells-develop-cytotoxic
7 https://www.cell.com/immunity/fulltext/S1074-7613(00)80218-6

jondoeuk

09/12/20 1:04 PM

Post #157

Re: #156: @jondoeuk - Hopefully, trials testing these improvements will start early

Lyell plan to use defined cell populations [1], improve ex vivo expansion [2-4], and a novel co-stim [5].

Refs:
1 https://www.nature.com/articles/leu2015247
2 https://www.sciencedirect.com/science/article/abs/pii/S1535610820302543
3 https://cancerres.aacrjournals.org/content/75/2/296.long
4 https://link.springer.com/article/10.1007%2Fs00262-012-1378-2
5 https://www.nature.com/articles/s41586-019-1805-z

jondoeuk

09/08/20 4:41 PM

Post #156

Re: #155: @jondoeuk - A new trial testing the NY-ESO-1 TCR-T cell

Hopefully, trials testing these improvements will start early next year https://www.fiercebiotech.com/biotech/gsk-taps-lyell-immunopharma-to-take-cell-therapy-to-next-level

jondoeuk

09/08/20 3:29 PM

Post #155

A new trial testing the NY-ESO-1 TCR-T cell therapy product [1] which either co-expresses a CD8a [2] or dnTGFßRII [2].

Refs:
1 https://clinicaltrials.gov/ct2/show/NCT04526509
2 (Some of the R&D was conducting with ADAP) https://www.adaptimmune.com/our-company/perspectives/detail/1153/jon-silk-talks-about-our-next-generation-research

MustBeTheTruth Free

08/09/20 10:16 AM

Post #154

Better Development Tools for a New Golden Era of Psychopharmacology

https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/

T695

08/05/20 10:57 PM

Post #153

Re: #152: @T695 - Calls for next month

Calls might sky rocket tomorrow

T695

07/31/20 5:08 PM

Post #152

Calls for next month

BottomBounce Free

05/18/20 3:26 PM

Post #151

Re: #104: @oscaraft - GSK to skyrocket to $100+ with Ebola Vaccine

Trump promises Cincinnati rally that US will end AIDS epidemic and find a cure for childhood cancer 'very shortly'

https://www.businessinsider.com/trump-cincinnati-promises-cure-cancer-and-aids-very-shortly-2019-8

BottomBounce Free

05/18/20 1:29 PM

Post #150

Re: #135: @Don'tDrinkTheKoolAid - Yep 39 now with 5% divvy I don't

$GSK Democratic-run House approves its $3 trillion relief measure in vote late Friday https://www.marketwatch.com/story/next-coronavirus-aid-package-expected-to-become-reality-in-june-at-the-earliest-as-house-prepares-to-pass-its-bill-on-friday-2020-05-15?mod=mw_more_headlines

BottomBounce Free

05/18/20 1:19 PM

Post #149

Re: #140: @I Need Money - Certainly a great LONG term hold. ;)

Here's Why Investors Should Follow Sanofi $SNY and GlaxoSmithKline's $GSK New #Coronavirus #COVID19
Collaboration

https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx

BottomBounce Free

05/18/20 1:00 PM

Post #148

Re: #139: @Don'tDrinkTheKoolAid - YIKES haha nice up tick with a great divvy.

**** BREAKING HIV $GSK <<<< Drug giant GSK today declared a major breakthrough on a new HIV treatment it was trialling in patients that could prevent the spread of the disease. https://www.standard.co.uk/business/drug-giant-gsk-sees-major-breakthrough-on-hiv-treatment-a4442996.html

Nebuchadnezzar Free

03/25/20 9:12 PM

Post #146

Re: #140: @I Need Money - Certainly a great LONG term hold. ;)

GSK-especially now in current market turmoil $35 looks XTRA tasty

BottomBounce Free

10/29/19 1:13 PM

Post #145

Re: #122: @pearsby09 - For 2016, it's been all about TAF -

Sci-B-Vac data is in December. That's the drug beating $GSK's Engerix-B

The infection prevention rate for $VBIV 91.4% for Sci-B-Vac

The infection prevention rate for $GSK 76.5% for Engerix-B

BottomBounce Free

10/25/19 11:29 AM

Post #144

Re: #127: @Trend-Setter - Mymetics to Present New Preclinical Data on Thermostable

$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK -2.8%) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

BottomBounce Free

10/24/19 6:25 PM

Post #143

Re: #140: @I Need Money - Certainly a great LONG term hold. ;)

$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK ) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent

BottomBounce Free

10/23/19 4:37 PM

Post #142

Re: #141: @Robbinhood101 - Watch this one go up with Tesaro approval.

$GSK and $VBIV VBI Vaccines teams up with Glaxo on therapeutic cancer vaccine https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent

Robbinhood101 Free

10/23/19 3:10 PM

Post #141

Watch this one go up with Tesaro approval.

I Need Money Free

10/06/19 3:41 PM

Post #140

Re: #139: @Don'tDrinkTheKoolAid - YIKES haha nice up tick with a great divvy.

Certainly a great LONG term hold. ;)

Don'tDrinkTheKoolAid Grandfathered

10/06/19 3:16 PM

Post #139

Re: #138: @I Need Money - $41.99 now. :)

YIKES haha nice up tick with a great divvy.

I Need Money Free

10/06/19 7:40 AM

Post #138

Re: #135: @Don'tDrinkTheKoolAid - Yep 39 now with 5% divvy I don't

$41.99 now. :)

Don'tDrinkTheKoolAid Grandfathered

12/19/18 9:42 AM

Post #135

Re: #133: @Dhubbard5 - I agree with your theory completely make total sense.

Yep 39 now with 5% divvy I don't own it now :(!

DewDiligence PremiumMember

12/19/18 9:18 AM

Post #134

GSK, PFE form consumer-health JV: #msg-145552190.

Dhubbard5

12/19/18 9:10 AM

Post #133

Re: #131: @Don'tDrinkTheKoolAid - Buy anything below 36 not much down side risk.

I agree with your theory completely make total sense.

debunker1

06/13/18 7:33 AM

Post #132

Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.

Don'tDrinkTheKoolAid Grandfathered

03/04/18 2:40 PM

Post #131

Buy anything below 36 not much down side risk.

Trend-Setter Free

02/08/18 3:04 PM

Post #130

Re: #127: @Trend-Setter - Mymetics to Present New Preclinical Data on Thermostable

Copy of Presentation:

https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/ (downloadble)

Older

GlaxoSmithKline (GSK)

Followers	21	Posters	74
Posts (Today)	0	Posts (Total)	184
Created	03/18/04	Type	Free
Moderators

GlaxoSmithKline plc
Stockley Park West
Uxbridge, UB11 1BT
United Kingdom - Map
Stockley Park West, Uxbridge, United Kingdom
Phone: 44 20 8990 9000
Fax: 44 20 8990 4321

Web Site: http://www.gsk.com

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical and consumer health-related products. Its Pharmaceuticals segment manufactures prescription drugs and vaccines that are used in various therapeutic areas, including central nervous system, respiratory, anti-viral, anti-bacterial, oncology and emesis, metabolic, cardiovascular, and urogenital. This segment offers Seretide/Advair for asthma and chronic obstructive pulmonary disease (COPD); Avandia for the treatment of type 2 diabetes; Lamictal for epilepsy and bipolar disorder; Wellbutrin, an anti-depressant; Zofran to prevent nausea and vomiting associated with chemotherapy and radiotherapy for cancer; Valtrex for herpes; Coreg for heart disease; and Imigran/Imitrex for migraine and cluster headache. Its products also include Augmentin for the treatment of bacterial infections; Seroxat/Paxil for the treatment of depressive disorder, panic, obsessive compulsive disorder, post traumatic stress disorder, social anxiety disorder, and generalized anxiety disorder; and Flixotide/Flovent, an inhaled steroid for the treatment of inflammation associated with asthma and COPD. The company's Consumer Healthcare segment offers over-the-counter medicines, oral care, and nutritional healthcare products. Its products comprise Lucozade energy and sports drinks; Aquafresh and Sensodyne toothpastes and mouthwashes; Aquafresh and Dr Best toothbrushes; Panadol, a paracetamol/acetaminophen analgesic; Horlicks, a milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in the United States, Europe, Japan, the Asia Pacific, the Middle East, Latin America, Africa, and Canada. It has agreements with Anacor Pharmaceuticals, Inc.; Oncomed Pharmaceuticals, Inc.; Santaris Pharma A/S; and Targacept, Inc. The company was founded in 1935 and is headquartered in Uxbridge, the United Kingdom.